New triple cream takes on melasma in Head-to-Head trial

NCT ID NCT07508098

Completed Disease control Sponsor: Pak Emirates Military Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 trial tested whether a triple-combination cream (containing N-acetylcysteine, hydroquinone, and triamcinolone acetate) works better than standard 4% hydroquinone cream for facial melasma. Fifty middle-aged men and women applied one of the creams twice daily for 8 weeks. The main goal was to see how many achieved at least a 60% reduction in their melasma severity score.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Triple combination cream (4.7% N-acetylcysteine, 2% hydroquinone, 0.1% triamcinolone acetate) and 4% hydroquinone cream
What this could lead to: If the triple cream works better, it could offer a more effective topical option for managing melasma with fewer side effects.
What could go wrong: This is a small, single-site study with only 50 participants, so results may not apply to everyone. Melasma often requires ongoing treatment, and any improvement may not be permanent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELASMA (FACIAL MELASMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELASMA (FACIAL MELASMA)

Contacts and locations

Locations

Dermatology Department of Tertiary Care Hospital

Rawalpindi, Punjab Province, 46000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.